News
Bristol-Myers Squibb Foundation Announces Grants Focused on Prevention, Diagnosis and Care of Hepatitis B and Hepatitis C in Asia
The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B and hepatitis C in China and India as part of its Delivering Hope™: Awareness, Prevention and Care umbrella program which is...
News
Bayer signs agreement to buy animal health business from KMG Chemicals
Bayer HealthCare, a subgroup of Bayer AG, has signed an agreement to acquire the animal health business from Texas based KMG Chemicals Inc. for executing its strategy to strengthen animal health portfolio. With a wide variety...
News
US FDA accepts Santarus’ Uceris NDA for induction of remission of active ulcerative colitis
The US Food and Drug Administration has accepted for filing the Santarus Inc.'s New Drug Application for Uceris tablets 9 mg. Pursuant to Prescription Drug User Fee Act guidelines, Santarus expects the FDA will complete its review or otherwise...
News
Merck Serono licenses Threshold cancer drug
Merck Serono, a unit of German pharmaceutical manufacturer Merck, has signed a licensing agreement with US-based biotechnology firm Threshold Pharmaceuticals for the development and commercialisation of TH-302. TH-302 is Threshold's small molecule hypoxia-targeted drug, designed...
News
New cost-cutting Medicaid rule could save US billions
A newly proposed cost-cutting rule implemented into the US Medicaid programme could save the country up to $17.7bn over five years, say US health officials. The proposed rule on prescription drugs purchased through the state...
News
Shire partners Sangamo to develop hemophilia treatments
Shire has signed a collaboration and license agreement with Sangamo Bioscience to develop therapeutics for hemophilia and other monogenic diseases using Sangamo's zinc finger DNA-binding protein (ZFP) technology. Under the collaboration agreement, Shire will...
News
NanoViricides files FluCide pre-IND to FDA
NanoViricides has submitted a pre- Investigational New Drug (IND) briefing document of its anti-influenza drug candidate, FluCide to the US Food and Drug Administration (FDA). In a lethal influenza infection mouse model, FluCide has...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read